(WAY) Waystar Holding Common Stock - Overview

Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 3.719m USD | Total Return: -49.9% in 12m

Healthcare Payments, Revenue Cycle, Claim Management, Financial Analytics
Total Rating 37
Safety 58
Buy Signal -0.59
Health Information Services
Industry Rotation: +9.7
Market Cap: 3.72B
Avg Turnover: 47.9M
Risk 3d forecast
Volatility59.1%
VaR 5th Pctl9.85%
VaR vs Median1.15%
Reward TTM
Sharpe Ratio-1.36
Rel. Str. IBD1.7
Rel. Str. Peer Group26.5
Character TTM
Beta0.696
Beta Downside0.836
Hurst Exponent0.495
Drawdowns 3y
Max DD60.46%
CAGR/Max DD-0.03
CAGR/Mean DD-0.11
EPS (Earnings per Share) EPS (Earnings per Share) of WAY over the last years for every Quarter: "2021-06": null, "2021-09": null, "2021-12": null, "2022-03": null, "2022-06": null, "2022-09": null, "2022-12": null, "2023-03": null, "2023-06": null, "2023-09": null, "2023-12": null, "2024-03": -0.04, "2024-06": 0.04, "2024-09": 0.14, "2024-12": 0.29, "2025-03": 0.16, "2025-06": 0.36, "2025-09": 0.37, "2025-12": 0.36, "2026-03": 0.42,
Last SUE: 0.38
Qual. Beats: 0
Revenue Revenue of WAY over the last years for every Quarter: 2021-06: 135.84, 2021-09: 147.403, 2021-12: 163.162, 2022-03: 172.4, 2022-06: 173.379, 2022-09: 177.973, 2022-12: 182.101, 2023-03: 191.083, 2023-06: 195.969, 2023-09: 197.263, 2023-12: 206.695, 2024-03: 224.792, 2024-06: 234.543, 2024-09: 240.112, 2024-12: 244.102, 2025-03: 256.435, 2025-06: 270.654, 2025-09: 268.651, 2025-12: 303.538, 2026-03: 313.874,
Rev. CAGR: 17.28%
Rev. Trend: 99.8%
Last SUE: 0.25
Qual. Beats: 0

Warnings

Altman Z'' 0.48 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: WAY Waystar Holding Common Stock

Waystar Holding Corp. (WAY) operates a cloud-based software-as-a-service (SaaS) platform designed to automate healthcare payment cycles. The company’s technology facilitates financial clearance, claim management, denial prevention, and revenue capture for healthcare providers. Headquartered in Lehi, Utah, the firm focuses on reducing administrative friction between providers and payers.

The healthcare technology sector increasingly relies on interoperability to manage complex billing codes and regulatory requirements. Waystar’s business model utilizes a recurring revenue structure, typical for enterprise software providers aiming to improve clinical integrity and reporting accuracy. Detailed historical performance metrics for this ticker are available on ValueRay for those conducting deeper due diligence.

Headlines to Watch Out For
  • Cloud-based software adoption accelerates healthcare revenue cycle digitization
  • Expansion of health system provider network drives recurring subscription revenue
  • Regulatory changes in healthcare reimbursement complexity increase demand for analytics
  • Strategic acquisitions expand total addressable market within medical payment processing
  • High interest rates impact valuation multiples for high-growth SaaS platforms
Piotroski VR-10 (Strict) 6.5
Net Income: 126.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.79 > 1.0
NWC/Revenue: 14.41% < 20% (prev 30.69%; Δ -16.28% < -1%)
CFO/TA 0.06 > 3% & CFO 330.3m > Net Income 126.1m
Net Debt (1.33b) to EBITDA (429.2m): 3.11 < 3
Current Ratio: 1.76 > 1.5 & < 3
Outstanding Shares: last quarter (195.2m) vs 12m ago 8.00% < -2%
Gross Margin: 65.22% > 18% (prev 0.67%; Δ 6.46k% > 0.5%)
Asset Turnover: 22.12% > 50% (prev 21.11%; Δ 1.01% > 0%)
Interest Coverage Ratio: 3.51 > 6 (EBITDA TTM 429.2m / Interest Expense TTM 79.9m)
Altman Z'' 0.48
A: 0.03 (Total Current Assets 386.6m - Total Current Liabilities 220.0m) / Total Assets 5.84b
B: -0.01 (Retained Earnings -65.5m / Total Assets 5.84b)
C: 0.05 (EBIT TTM 280.6m / Avg Total Assets 5.23b)
D: -0.03 (Book Value of Equity -62.8m / Total Liabilities 1.90b)
Altman-Z'' = 0.48 = B
Beneish M -2.90
DSRI: 0.99 (Receivables 172.5m/147.3m, Revenue 1.16b/975.2m)
GMI: 1.02 (GM 65.22% / 66.79%)
AQI: 1.03 (AQ_t 0.92 / AQ_t-1 0.89)
SGI: 1.19 (Revenue 1.16b / 975.2m)
TATA: -0.03 (NI 126.1m - CFO 330.3m) / TA 5.84b)
Beneish M = -2.90 (Cap -4..+1) = A
What is the price of WAY shares?

As of June 01, 2026, the stock is trading at USD 19.91 with a total of 2,081,489 shares traded.
Over the past week, the price has changed by +5.71%, over one month by -6.85%, over three months by -24.15% and over the past year by -49.94%.

Is WAY a buy, sell or hold?

Waystar Holding Common Stock has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy WAY.

  • StrongBuy: 9
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the WAY price?
Analysts Target Price 34.3 72.1%
Waystar Holding Common Stock (WAY) - Fundamental Data Overview as of 30 May 2026
Market Cap USD = 3.72b (3.72b USD * 1.0 USD.USD)
P/E Trailing = 28.9403
P/E Forward = 11.5741
P/S = 3.2154
P/B = 0.9446
Revenue TTM = 1.16b USD
EBIT TTM = 280.6m USD
EBITDA TTM = 429.2m USD
Long Term Debt = 1.46b USD (from longTermDebt, last quarter)
Short Term Debt = 19.8m USD (from shortTermDebt, last quarter)
Debt = 1.49b USD (corrected: LT Debt 1.46b + ST Debt 19.8m) + Leases 16.5m
Net Debt = 1.33b USD (calculated: Debt 1.49b - CCE 158.9m)
Enterprise Value = 5.05b USD (3.72b + Debt 1.49b - CCE 158.9m)
Interest Coverage Ratio = 3.51 (Ebit TTM 280.6m / Interest Expense TTM 79.9m)
EV/FCF = 17.19x (Enterprise Value 5.05b / FCF TTM 294.0m)
FCF Yield = 5.82% (FCF TTM 294.0m / Enterprise Value 5.05b)
FCF Margin = 25.41% (FCF TTM 294.0m / Revenue TTM 1.16b)
Net Margin = 10.90% (Net Income TTM 126.1m / Revenue TTM 1.16b)
Gross Margin = 65.22% ((Revenue TTM 1.16b - Cost of Revenue TTM 402.3m) / Revenue TTM)
Gross Margin QoQ = 69.08% (prev 56.16%)
Tobins Q-Ratio = 0.87 (Enterprise Value 5.05b / Total Assets 5.84b)
Interest Expense / Debt = 5.35% (Interest Expense 79.9m / Debt 1.49b)
Taxrate = 27.64% (16.5m / 59.8m)
NOPAT = 203.0m (EBIT 280.6m * (1 - 27.64%))
Current Ratio = 1.76 (Total Current Assets 386.6m / Total Current Liabilities 220.0m)
Debt / Equity = 0.38 (Debt 1.49b / totalStockholderEquity, last quarter 3.94b)
Debt / EBITDA = 3.11 (Net Debt 1.33b / EBITDA 429.2m)
Debt / FCF = 4.53 (Net Debt 1.33b / FCF TTM 294.0m)
Total Stockholder Equity = 3.55b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.41% (Net Income 126.1m / Total Assets 5.84b)
RoE = 3.48% (Net Income TTM 126.1m / Total Stockholder Equity 3.62b)
RoCE = 5.53% (EBIT 280.6m / Capital Employed (Equity 3.62b + L.T.Debt 1.46b))
RoIC = 3.70% (NOPAT 203.0m / Invested Capital 5.48b)
WACC = 7.13% (E(3.72b)/V(5.21b) * Re(8.43%) + D(1.49b)/V(5.21b) * Rd(5.35%) * (1-Tc(0.28)))
Discount Rate = 8.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.41 | Cagr: 7.27%
[DCF] Terminal Value 77.97% ; FCFF base≈254.8m ; Y1≈292.1m ; Y5≈429.9m
[DCF] Fair Price = 26.78 (EV 6.47b - Net Debt 1.33b = Equity 5.14b / Shares 191.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.38 | # QB: 0
Revenue Correlation: 99.82 | Revenue CAGR: 17.28% | SUE: 0.25 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.40 | Chg30d=-1.02% | Revisions=-30% | Analysts=20
EPS next Quarter (2026-09-30): EPS=0.41 | Chg30d=-1.00% | Revisions=-22% | Analysts=20
EPS current Year (2026-12-31): EPS=1.64 | Chg30d=+0.85% | Revisions=+39% | GrowthEPS=+15.7% | GrowthRev=+16.9%
EPS next Year (2027-12-31): EPS=1.85 | Chg30d=-0.35% | Revisions=+18% | GrowthEPS=+12.5% | GrowthRev=+10.7%
[Analyst] Revisions Ratio: +39%